The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2'-deoxycytidine lesions by Luis Orta, M. et al.
This is a repository copy of The PARP inhibitor Olaparib disrupts base excision repair of 
5-aza-2'-deoxycytidine lesions.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/159268/
Version: Published Version
Article:
Luis Orta, M., Höglund, A., Calderón-Montaño, J.M. et al. (7 more authors) (2014) The 
PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2'-deoxycytidine lesions. 
Nucleic Acids Research, 42 (14). pp. 9108-9120. ISSN 0305-1048 
https://doi.org/10.1093/nar/gku638
© 2014 The Author(s). Published by Oxford University Press on behalf of Nucleic Acids 
Research. This is an Open Access article distributed under the terms of the Creative 
Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits 
unrestricted reuse, distribution, and reproduction in any medium, provided the original 
work is properly cited.
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
9108–9120 Nucleic Acids Research, 2014, Vol. 42, No. 14 Published online 29 July 2014
doi: 10.1093/nar/gku638
The PARP inhibitor Olaparib disrupts base excision
repair of 5-aza-2′-deoxycytidine lesions
Manuel Luis Orta1,2,†, Andreas Ho¨glund2,†, Jose´ Manuel Caldero´n-Montan˜o2,3,
Inmaculada Domı´nguez1, Estefanı´a Burgos-Moro´n3, Torkild Visnes2, Nuria Pastor1,
Cecilia Stro¨m2, Miguel Lo´pez-la´zaro3 and Thomas Helleday2,*
1Department of Cell Biology, Faculty of Biology, University of Seville, Avda. Reina Mercedes 6, 41012 Seville, Spain,
2Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical
Biochemistry and Biophysics, Karolinska Institute, S-171 21 Stockholm, Sweden and 3Department of Pharmacology,
Faculty of Pharmacy, University of Seville, c/Professor Garcı´a Gonza´lez, No. 2, 41012 Seville, Spain
Received February 11, 2014; Revised June 30, 2014; Accepted July 2, 2014
ABSTRACT
Decitabine (5-aza-2′-deoxycytidine, 5-azadC) is used
in the treatment of Myelodysplatic syndrome (MDS)
and Acute Myeloid Leukemia (AML). Its mechanism
of action is thought to involve reactivation of genes
implicated in differentiation and transformation, as
well as induction of DNA damage by trapping DNA
methyltranferases (DNMT) to DNA. We demonstrate
for the first time that base excision repair (BER) rec-
ognizes 5-azadC-induced lesions in DNA and medi-
ates repair. We find that BER (XRCC1) deficient cells
are sensitive to 5-azadC and display an increased
amount of DNA single- and double-strand breaks.
The XRCC1 protein co-localizes with DNMT1 foci af-
ter 5-azadC treatment, suggesting a novel and spe-
cific role of XRCC1 in the repair of trapped DNMT1.
5-azadC-induced DNMT foci persist in XRCC1 defec-
tive cells, demonstrating a role for XRCC1 in repair
of 5-azadC-induced DNA lesions. Poly (ADP-ribose)
polymerase (PARP) inhibition prevents XRCC1 relo-
cation to DNA damage sites, disrupts XRCC1–DNMT1
co-localization and thereby efficient BER. In a panel
of AML cell lines, combining 5-azadC and Olaparib
cause synthetic lethality. These data suggest that
PARP inhibitors can be used in combination with 5-
azadC to improve treatment of MDS and AML.
INTRODUCTION
5-aza-2′-deoxycytidine (5-azadC) and 5-azacytidine (5-
azaC) are synthetic cytidine analogues highly effective in
the treatment of myelodysplastic syndromes (MDS), with
5-azadC also showing good clinical response in older pa-
tients diagnosed with acute myeloid leukemia (AML) (1–
3). 5-azaC and 5-azadC were synthesized in the 60s as con-
ventional cytostatic drugs (4) but were later discovered to
demethylate DNA through their interactions with DNA
methyltransferases (DNMTs) (5).
It is well accepted that the antineoplastic properties
of these agents are due to two non-exclusive mech-
anisms. First, demethylation causes reactivation of
hypermethylated/silenced tumor suppressor genes and
second, DNMT–DNA adducts causes genome wide DNA
damage (6–8).
It has been suggested that the base excision repair path-
way (BER) could be involved in the excision of 5-azaC and
5-azadC from DNA (9). The BER pathway is initiated by
DNA glycosylases that recognize and excise aberrant bases
from DNA, generating an abasic (AP) site in DNA, further
processed by AP-endonuclease 1 (APE 1) to form a single-
strand break (SSB) in DNA. A DNA polymerase replaces
the missing nucleotide and a complex constituted by DNA
ligase and the X-ray repair cross-complementing protein 1
(XRCC1) inalizes repair by ligating DNA (10).
XRCC1 is well known to be essential for both BER and
SSB repair. XRCC1 deicient mice are embryonic lethal (11)
and XRCC1 deicient cells display increased levels of spon-
taneous  -H2AX and RAD51 foci (12), and are hypersen-
sitive to agents that induce SSBs or base damage (13,14).
In this paper we demonstrate for the irst time that BER
is required to repair DNA lesions induced by 5-azadC. BER
(XRCC1) deicient cells displayed reduced survival and in-
creased levels of single- and double-strand breaks (DSBs)
as well as chromosomal abnormalities. Our indings suggest
a novel and speciic role of XRCC1 in the repair of DNA
damage and survival of cancer cells following 5-azadC treat-
ment. We and others have previously shown that Olaparib
treatment traps PARP on the single strand DNA break in-
termediate generated during BER and prevents further re-
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pair (15,16). In this paper we show that 5-azadC in combi-
nation with the PARP inhibitor Olaparib blocks BER in-
duced by 5-azadC and leads to a synergistic induction of
cell death in a panel of AML cells. We believe that this
combination treatment warrants further investigation in the
hope that this could improve current best supportive care of
MDS and AML patients.
MATERIALS AND METHODS
Chemicals and plasmids
5-aza-2′-deoxycytidine and 5-azacytidine (Sigma) were dis-
solved in phosphate buffered saline (PBS) and stored at
−80oC. The plasmid expressing GFP-tagged DNMT1 was
a gift from Keith Robertson and the RFP-tagged XRCC1
plasmid was a gift fromHeinrich Leonhard, both described
previously (6,17). Olaparib (KU-0059436, AZD-2281) and
4-amino 1,8 naphthalimide (4-ANI) were dissolved in
DMSO, aliquoted and stored at −80oC. Methoxyamine
(MX) was purchased from Sigma and freshly dissolved in
PBS before use.
Cell lines and culture conditions
Chinese hamster ovary cells AA8 (wild-type) and EM9
(XRCC1 deicient) were cultured in McCoy’s 5A media.
EM9 cells stably transfected with an empty vector (EM9-
V) or with a vector encoding human XRCC1 (EM9-XH)
were a gift from Keith Caldecott and have been described
earlier (18). These cells were cultured in Dulbecco’s modi-
ied Eagle’s medium (DMEM), in the presence of geneticin
(G418) at a inal concentration of 1.5 mg/ml.
The AML cell line HL60 was obtained from ATCC,
whereas K652, KG1a, Mv4–11 and PL21 cells were kindly
provided by Dr So¨ren Lehmann, Karolinska Institutet,
Sweden. All AML cells were grown in RPMI 1640-
Glutamax. HeLa cells were obtained from ATCC and
grown in DMEM.
All cell lines were cultured with 10% fetal calf serum,
penicillin (50 U/ml) and streptomycin (50 g/ml), at 37◦C
in a 5% CO2 atmosphere.
Survival assay
EM9-XH and EM9-V cells were seeded in 10 cm Petri
dishes 4 h prior to 5-azadC or 5-azaC treatment for 24 h.
Colonies were ixed, stained (methylene blue dissolved in
methanol, 4 g/l) and counted after 7–10 days. The data
are plotted as percentage of survival referred to control
cells. Procedures for combination experiments are further
described in igure legends.
Cytogenetic spreads and DNA damage scoring
AA8 and EM9 cells were treated with 5-azadC for 24 h,
washed and kept in fresh medium for 12 h to recover. Chro-
mosome spreads were prepared as described previously (7).
Immunoluorescence
The cells were treated for 24 h with 5-azadC, washed and in-
cubated for 30 s with ice cold 0.1% Triton-X in PBS to pre-
extract soluble protein and then ixed in 4% paraformalde-
hyde at room temperature for 10 min. Inmunoluorescence
was carried out as previously described (7).
Cells with more than 10 or 20 foci were counted as posi-
tive for RAD51 or  -H2AX respectively. At least 200 nuclei
were counted on each slide.
For  -H2AX and 53Bp1 quantiication in AML HL60
cells, following 24 h exposure to 100 nM 5-azadC and/or 1
M Olaparib, cells were washed with PBS and incubated
for 20 min with cold methanol. Cells were washed again
with PBS and incubated for 10 min with 5% bovine serum
albumin (BSA), 0.1% Tween-20 and 0.1% Saponin in PBS.
All subsequent steps were performed with 0.1% Saponin in
the media. Cells were then incubated overnight at 4◦C with
primary antibodies, anti-phospho-histone H2AX (S139;
1:1000; Millipore) and anti-53Bp1 (1:1000; Bethyl). The
cells were then washed and incubated with secondary an-
tibodies goat anti-mouse IgG Alexa Fluor R© 488 (1:1000,
Life technologies) and donkey anti-rabbit IgG IgG Alexa
Fluor R© 555 (1:1000, Life technologies). DNA was stained
with 100 nM 4,6 diamidino-2-phenylindole for 15 min. Fi-
nally, cells were attached to microscope slides by centrifu-
gation for 4 min at 600 rpm in a cytospin centrifuge and
processed for confocal microscope analysis. A total of 200
cells/slide were counted and cells with 10 or more co-
localized foci of phospho-histone H2AX and 53BP1 were
scored as positive.
Alkaline DNA unwinding technique experiments
Cells were treated with 50 M 5-azadC for 24 h together
with [3H]-TdR (7.1 kBq/ml), then lysed at different time
points and processed for the alkaline DNA unwinding
(ADU) technique to quantify DNA breaks.
In order to monitor the effect of PARP inhibition dur-
ing 5-azadC treatment, cells were cultured in the presence
of PARP inhibitor Olaparib (1 M) during the last 12 h
of treatment. The ADU technique was performed as previ-
ously described (15,19–21).
Transfection and co-localization procedures
All transient transfections were performed using
JetPRIME R© transfection reagent according to the manu-
facturer’s protocol (PolyPlus).
HeLa cells were transfected with DNMT1-GFP and
XRCC1-RFP plasmids and then treated with 5-azadC (15
M) alone or in the presence of Olaparib (1 M) for 24
h. The cells were ixed with 4% paraformaldehyde and
processed for confocal microscope analysis. Manders co-
localization indexwasmeasured using Fiji software (Coloc2
pluggin, where 1 means perfect co-localization and 0 no co-
localization).
For repair studies, EM9-XH and EM9-V cells were trans-
fected with DNMT1-GFP plasmid, treated with 15 M
5-azadC for 24 h and then allowed to recover in fresh
media for different time points. HeLa cells were similarly
transfected, treated and allowed to repair for different time
points with or without 1MOlaparib. Cells were then ixed
using 4% paraformaldehyde and mounted for microscopy.
Cells containing more than 10 foci were scored as positive.
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The data are represented as the percentage of cells with 5-
azadC induced foci.
Ethynyl deoxyuridine (EdU) incorporation to detect replicat-
ing cells
HeLa cells were transfected with the XRCC1-RFP plasmid
and treated with 15 M5-azadC for 24 h. In order to quan-
tify the XRCC1 foci-positive cells that were replicating at
the end of the treatment, cells were pulse-labeled for 30 min
with EdU and then ixed with 4% paraformaldehyde. EdU
staining was performed according to manufacturers proto-
col (CLICK-iT EdU R© 488, Invitrogen).
Resazurin proliferation assay
Resazurin sodium salt (Sigma-Aldrich) was added at a i-
nal concentration of 0.1 mg/ml to the cell growth media.
The plates were then incubated for 6 h before analysis using
luorescence readout at 535/590 nm in an EnVision Mul-
tilabel reader (Perkin ElmerTM). The absorbance was nor-
malized against background levels and the data processed in
MS Excel by standard techniques before statistical analysis
in CompusynTM to generate combination index plots.
Flow cytometry
For analysis of cell death by apoptosis, cells were processed
according to the instructions in BDFITCAnnexinVApop-
tosis Detection Kit I (BD PharmingenTM), with the excep-
tion of the addition of 7AAD (BD PharmingenTM) instead
of propidium iodide to stain DNA. The samples were an-
alyzed in a BD FACS Calibur, detecting Annexin-V in the
FL1 and 7AAD in the FL3 channel.
Cellular fractionation and SDS-PAGE analysis
We performed fractionation as described before (22). To en-
sure equal loading of chromatin fractioned protein, each
time point of the experiment was counted separately us-
ing the Bio-Rad TC20TM cell counter. 1 × 106 cells were
fractioned for each sample. All protein were separated on
sodium dodecylsulphate-polyacrylamide gel electrophore-
sis (SDS-PAGE) gels and subsequently transferred to nitro-
cellulose membranes. All subsequent steps were carried out
in TBS–Tween (10 mM Tris-HCl, pH 7.6, 150 mM NaCl
and 0.05% Tween-20) either containing 5% milk (blocking
and antibody incubations) or 5% BSA (phospho-speciic
antibody incubations). Antibody binding was visualized by
enhanced chemiluminescence using the SuperSignal West
Dura or Pico reagents from PierceTM and a Chemidoc MP
system from Bio-RadTM. Antibodies used; Actin (Abcam),
DNMT1 (Abcam), cleaved-Parp (Cell signaling),  -H2AX
(Millipore), HistoneH3 (Santa Cruz), GAPDH (Abcam)
and Ku70 (Santa Cruz).
In vitro 5-azadC-DNA excision assay
Genomic DNA prepared from EM9-V cells exposed to
0.1 M [6–3H]5-azadC was incubated with whole cell ex-
tracts prepared by lysing cells on ice in three packed cell
volumes in lysis buffer (25 mM Tris-HCl pH 8.0, 200
mM KCl, 2 mM ethylenediaminetetraacetic acid, 1 mM
DL-Dithiothreitol (DTT),1× Complete protease inhibitors
(Roche), 0.5% v/v NP-40 and 40% glycerol). Following in-
cubation, acid-insolublematerial was removed by precipita-
tion in 5% TCA and centrifugation at 16 000 g for 15 min.
Radioactivity in the supernatant was counted in a Packard
Tri-Carb liquid scintillation counter. DNA from cells ex-
posed to [3H]TdR was used as control.
Statistical analysis
To determine the signiicance of our results, Student’s t-test
was used. Statistical analysis and plotting of the results were
performed using GraphPad Plus, Sigma Plot or MS Excel.
The results originate from at least two independent experi-
ments and are presented asmean± standard deviation (SD)
of the mean. Differences were considered signiicant when
P < 0.05 (*) or P < 0.01 (**). Non-statistically signiicant
differences were labeled as n.s.
RESULTS
BER deicient cells are hypersensitive to 5-azadC
As an aberrant base, it is possible that 5-azadC is recog-
nized and repaired by an excision repair mechanism. There
are numerous DNA glycosylases that potentially could ex-
ert this function; however, downstream repair depends on
a functional XRCC1 protein. To be able to monitor all re-
pair events, we used XRCC1 defective cells to determine
a potential role of BER in repair of lesions induced by 5-
azadC. Chinese hamster ovary (CHO) EM9 cells deicient
for XRCC1 expression and its parental wild-type AA8 cells
were plated at low density for clonogenic survival and then
treated with increasing doses of 5-azadC. EM9 cells were
shown to be signiicantly more sensitive to 5-azadC than
XRCC1 WT AA8 cells (Figure 1A).
We next wanted to determine whether the dramatic sen-
sitization seen in EM9 cells was due to a lack in the repair
of 5-azadC induced lesions. Chromosomal aberrations were
analyzed in XRCC1 deicient EM9 and parental AA8 cells
treated with 5-azadC after a 12-h repair period. Analysis of
the percentage of cells with 10 or more aberrations showed
a signiicant difference between AA8 and EM9 cells (Fig-
ure 1B and C). At the highest concentration of 5-azadC
(15uM), 34% of the EM9 cells and 3% of the AA8 cells dis-
played more than 10 aberrations (*P < 0.05).
Abasic sites are generated when the BER pathway pro-
cesses damaged nucleotides. In order to determine if aba-
sic sites are indeed generated, implicating engagement of
BER, we probed 5-azadC treated AA8 and EM9 cells with
an abasic site speciic biotinylated probe (ARP), and de-
tected the luorescence of biotinylated AP-sites by low cy-
tometry (23). This analysis pointed to an increase in abasic
sites independent of XRCC1 status (Supplementary Figure
S1). As the ARP probe also presents reactivity with car-
bonyl groups present in proteins, we analyzed the ARP lu-
orescence by microscope and found that 5-azadC treated
cells present more luorescence in the nucleus as compared
to control cells, which suggest that abasic sites are gener-
ated (Supplementary Figure S2). To further show that aba-
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Figure 1. XRCC1 deicient cells are hypersensitive to 5-azadC. (A) Clonogenic survival after 24-h treatment with increasing doses of 5-azadC in EM9
(XRCC1 deicient) and AA8 (XRCC1 wild-type) cells. After treatments, cells were allowed to form colonies in fresh media for 7-days. The means and SD
from three independent experiments are shown. (B) Quantiication of chromosomal aberrations after a 24-h treatment with 5-azadC in AA8 and EM9
cells (wild-type or XRCC1 deicient cells respectively). Cells were treated for 24 h and then allowed to repair for 12 h in drug free media. Cells with 10 or
more chromosomal aberrations were scored as positive. The means and SD of two independent experiments are shown. (C) Representative metaphases of
AA8 and EM9 cells treated with 15 M 5-azadC. (D) MX sensitizes AA8 and EM9 cells to 5-azadC. Cells were treated with increasing concentrations
of 5-azadC together with 2.5 mM of MX for 24 h. Media was then changed and cultures were treated again with MX for another 24 h. After 7 days,
colonies were ixed and stained using methylene blue. The data are plotted as percentage of survival compared to control cells. The means and SD of
two independent experiments are shown. (E) XRCC1 detection by western blot in EM9-V and EM9-XH cells. GADPH was used as loading control. (F)
Clonogenic survival after 24-h treatment with increasing doses of 5-azadC in EM9-V (XRCC1 deicient) and EM9-XH (XRCC1 complemented) cells.
After treatments, cells were allowed to form colonies in fresh media for 7 days. The means and SD from two to three independent experiments are shown.
(G) EM9-XH and EM9-V cells were treated for 24 h with 5-azadC (50 M) and then allowed to repair in drug-free media for different times at which they
were lysed and processed for ADU technique. The data are represented as fold increase in SSBs relative to control cells (value: 1). The means and SD of
two independent experiments are shown.
sic sites are generated, we utilized the abasic site speciicity
of the drug MX (24). MX creates adducts by binding to the
abasic site and inhibiting the subsequent incision by APE1.
If the lesions induced by 5-azadC are repaired through the
BER pathway, sub-lethal doses of MX would cause syner-
gistic lethality in combination with 5-azadC (25). Indeed,
we observed a sensitization to 5-azadC in XRCC1WTAA8
cells and EM9 cells after a sub-lethal dose ofMX treatment
pointing to an involvement of the BER pathway (Figure 1D
and Supplementary Figure S3A). This effect was also dose
dependent as increasing the dose of MX further sensitized
AA8 cells to 5-azadC (Supplementary Figure S3B).
We next wanted to validate our data with EM9 cells com-
plemented with XRCC1 WT expression. EM9 cells either
stably transfected with either an empty vector (EM9-V) or
with a vector containing WT human XRCC1 (EM9-XH)
were treated with 5-azadC and plated for clonogenic sur-
vival. Indeed, EM9-V cells were found to be more sensitive
to treatment than XRCC1 complemented EM9-XH cells
(Figure 1E and F). These cells were also found to be hyper-
sensitive to 5-azaC, another synthetic cytidine analog (Sup-
plementary Figure S4).
Because XRCC1 deicient cells are defective in the repair
of SSBs (13,14) we also wanted to examine the repair kinet-
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ics of SSBs using the alkalineDNAunwinding (ADU) tech-
nique (15,19). XRCC1 deicient cells treated with 5-azadC
displayed increased levels of strand breaks that persisted
for 12 h post treatment compared to complemented cells,
in which we could not ind a substantial induction in SSBs
(Figure 1G).
In conclusion, our data suggest that BER is an active
mechanism in the repair of 5-azadC lesions.
BERdeiciency leads to induction ofDSBs that are substrates
for homologous recombination after 5-azadC treatment
When a replication fork encounters a SSB or an unrepaired
base lesion, one potential outcome collapses and it converts
into aDSB (12). These collapsed forks are known substrates
for homologous recombination (HR) (26). BER (XRCC1)
deicient cells have been reported to have increased spon-
taneous levels of  -H2AX and RAD51 foci, which are
markers of DSBs and HR respectively (12). We could ob-
serve increased levels of both  -H2AX and RAD51 foci
at all concentrations of 5-azadC tested in XRCC1 dei-
cient cells (EM9-V) (Figure 2A and B, P < 0.05 and P <
0.01).  -H2AX and RAD51 foci co-localized (Manders co-
localization index = 0.84 ± 0.09, n = 20), showing that
the induced DSBs are indeed repaired by HR (Figure 2C).
Taken together, these data demonstrate that in the absence
of XRCC1, 5-azadC induced lesions result in higher levels
of DSBs and HR repair activation.
XRCC1 co-localizes with trapped DNMT1 after 5-azadC
treatment
It is well known that DNA damage caused by 5-azadC is
mediated by the trapping of DNMTs and subsequent for-
mation of protein–DNAadducts (6,8). Considering the dra-
matic phenotype observed when treating XRCC1 deicient
cells with 5-azadC, we wanted to test if XRCC1 is directly
involved in this repair. We transfected HeLa cells with two
separate plasmids expressing GFP-tagged DNMT1 and
RFP-tagged XRCC1 and treated them with 5-azadC for 24
h. As previously reported (6), 5-azadC treatment induced
a dramatic accumulation of DNMT1 foci (Figure 3A). We
also observed an increase in XRCC1 foci, which is in agree-
ment with the responsiveness of cells to 5-azadC. Interest-
ingly, our data also revealed a high level of co-localization of
XRCC1 and trappedDNMT, suggesting that XRCC1 plays
a role in the repair of 5-azadC induced DNMT1 adducts
(Figure 3B). Since both XRCC1 and DNMT1 are proteins
known to be associated with active replication forks we
wanted to exclude the possibility that the observed inter-
action occurred at active replication forks using the thymi-
dine analog EdU (27,28). Indeed, the interaction between
XRCC1 and DNMT1 following 5-azadC treatment was
shown to be independent ofDNA replication, sinceXRCC1
positive cells did not stain positive for EdU (Figure 3C and
D). In conclusion, our data suggest that BER proteins have
an active role in the repair of 5-azadC trapped DNMT1–
DNA adducts.
Repair of DNMT1–DNA adducts is delayed in an XRCC1
dependent manner
We propose that BER has a role in the repair of incorpo-
rated 5-azadC; if this is indeed the case, one would expect
5-azadC to be excised fromDNA following repair. To mon-
itor this, we incubated [6–3H] 5-azadC treated EM9-V ge-
nomic DNA with EM9-V and -XH whole cell lysate and
then precipitated insoluble DNA and analyzed radioactiv-
ity in the remaining supernatant. Both EM9 V and -XH
lysate were able to release radioactivity from DNA con-
taining [6–3H] 5-azadC but not [3H]TdR, demonstrating
that excision of 5-azadC precedes the generation of abasic
sites in aXRCC1 independentmanner (Figure 4A).We next
wanted to see if DNMT1–DNA adducts persist for longer
times inXRCC1deicient cells and if this would help explain
the observed increase in DSBs. We monitored the repair of
DNMT1 foci in EM9-V and -XH cells transfected with a
DNMT1-GFP construct. The cells were treated for 24 h
with 5-azadC and then left to recover in fresh media (Fig-
ure 4B). Both cell lines displayed similar levels of DNMT1
foci positive cells after the treatment with 5-azadC. How-
ever, EM9-XH repaired the DNMT1 foci faster than the
XRCC1 deicient EM9-V cells over the course of 48 h,
indicative of defective repair in the XRCC1 deicient set-
ting. To verify these indings, we also performed a chro-
matin fractionation assay to determine the amount of en-
dogenously expressedDNMT1 bound to chromatin after 5-
azadC treatment. XRCC1 deicient EM9-V cells displayed
more chromatin-bound DNMT1 with delayed repair com-
pared to complemented EM9-XH cells (Figure 4C and D
and Supplementary Figure S5A). When looking at EM9-V
and -XH cells transfected with DNMT1-GFP, similar lev-
els of chromatin bound DNMT1 were found after 5-azadC
exposure but again, EM9-V cells displayed slower repair
kinetics (Supplementary Figure S5B). In conclusion, our
data demonstrate that BER is activated following 5-azadC
exposure and that the repair kinetics of chromatin bound
DNMT1 and randomly incorporated 5-azadC is severely
affected in XRCC1 deicient cells, leading to an increase in
DSBs.
PARP inhibition abolishes 5-azadC-induced
XRCC1/DNMT1 co-localization, interrupts BER and
generates DSBs which are repaired by HR.
We and others have previously shown that PARP-1 has the
capacity to bind the SSB intermediates formed during BER
(15,16). PARP inhibition traps PARP-1 at the SSB inter-
mediate, thus creating an eficient block of further repair
(15,16,29). PARP inhibitors are currently being evaluated
in clinical trials because of the synthetic lethality caused in
cancers with genetic makeups that renders HR repair in-
active, such as BRCA1 or BRCA2 mutations (30,31). Due
to SSB repair defects in PARP inhibited cells and the ob-
vious clinical interest in PARP inhibitors, we wanted to
evaluate if PARP inhibition could block 5-azadC-induced
BER and sensitize cells to treatment. To this end, we trans-
fected HeLa cells with plasmids expressing GFP-tagged
DNMT1 and RFP-tagged XRCC1. Co-treatment with 5-
azadC and Olaparib led to a dramatic reduction in the ra-
tio of XRCC1 but not DNMT1 foci compared to 5-azadC
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Figure 2. XRCC1 deicient cells display increased levels of  -H2AX and RAD51 foci induced by 5-azadC. (A and B) Quantiication of  -H2AX and
RAD51 foci positive cell in EM9-XH and EM9-V cells after a 24-h treatment with increasing concentrations of 5-azadC. Cells with more than 20 or 10 foci
respectively were scored as positive respectively. The means and SD of three independent experiments are shown. (C) Co-localization between  -H2AX
and RAD51 foci induced by 5-azadC.
treated cells (Figure 5A), in agreement with the proposed
function of PARP in the assembly of XRCC1 (32). Fur-
thermore, when we irst treated these cells with Olaparib,
we found no co-localization betweenXRCC1 andDNMT1,
suggesting a role of PARP in the loading of XRCC1 onto
trapped DNMT1 (compare Figure 5B and Figure 3B, Sup-
plementary Figure S6). These data suggest that PARP in-
hibition disrupt the repair of 5-azadC induced lesions. We
next wanted to know if the repair of 5-azadC induced
DNMT1–DNA adducts is affected by PARP inhibition.
Clearly, PARP inhibited cells displayed a severe defect in the
clearance of DNMT1 foci (Figure 5C). Also, SSBs induced
by 5-azadC in EM9-XH cells (XRCC1 wild-type) were in-
creased in the presence of Olaparib (Figure 5D). We also
observed that EM9-V and Olaparib treated EM9-XH cells
displayed similar levels of SSBs, indicating an equally im-
portant role for these proteins in repair of 5-azadC induced
lesions. Moreover, when cells were treated with 10 M of
5-azadC together with Olaparib, we observed a synergistic
accumulation of SSBs in XRCC1 deicient cells (average 27
000 versus 9000 SSBs respectively, P < 0.01) (Figure 5D).
This data agrees with our previous hypothesis that PARP
inhibitors trap SSB intermediates of BER (15). Similar data
were obtained using 4-ANI, another PARP inhibitor (Sup-
plementary Figure S7). Importantly, SSBs were detected 2
h after 5-azadC exposure in 4-ANI treated cells, showing
that SSBs are early intermediates of repair (Supplementary
Figure S8).
Next, we wanted to investigate if trapped intermediates
of BER could be converted into DSBs and trigger HR. In
HeLa cells, a combined treatment of 5-azadC and Olaparib
lead to increased levels of  -H2AX and RAD51 foci (Fig-
ure 5E and F) as compared with single treatments, suggest-
ing that HR has a role in the repair of 5-azadC lesions when
PARP is inhibited. This increase in DNA damage also dra-
matically reduced cell survival (Figure 5G). In conclusion,
our data show that PARP inhibition severely disrupts the
BER pathway following 5-azadC and that this damage en-
gage HR.
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Figure 3. XRCC1 co-localizes with DNMT1 foci preferentially in non-replicating cells. (A) Quantiication of cells positive for DNMT1 or XRCC1 foci
after treatment with 5-azadC. Cells with more than 10 foci were scored as positive. The means and SD of three independent experiments are shown. (B)
Co-localization of DNMT1 and XRCC1 foci in control and 5-azadC treated cells assessed by confocal microscopy. HeLa cells were transiently transfected
with plasmids encoding for DNMT1-GFP or XRCC1-RFP and treated with 5-azadC for 24 h. Overlaid images showing yellow signal are indicative of
co-localization between green and red foci. Experiments were repeated three times and representative images are shown. (C) In order to test if 5-azadC
induced XRCC1 foci are associated with replicating cells, XRCC1-RFP expressing cells were treated with 5-azadC for 24 h and incubated with EdU during
the last 30 min in order to label replicating cells (green signal). Slides were counterstained with DAPI (blue). The percentage of positive cells for XRCC1
foci (red) that were replicating at the end of the treatment are represented in (C). Similary to control cells, most of the positive cells for XRCC1 foci are not
replicating. Representative images are shown in (D).
PARP inhibition in combination with 5-azadC cause syn-
thetic lethality in acute myeloid leukemia cells
5-azadC (Decitabine) is an FDA approved drug for the
treatment of MDS and AML (33). The use of this demethy-
lating agent has proved to be a signiicant improvement over
previous best supportive care (34), but there are still non-
responding patients and those developing resistance to ther-
apy. In light of this, we wanted to evaluate if combiningOla-
parib with 5-azadC in established human AML cell lines
would render 5-azadC treatments more eficient. We used
a human AML cell line panel consisting of HL60, k562,
MV4–11, PL21 and KG1a. The cells were treated for 72 h,
after which the synthetic lethality of the drug–drug combi-
nation was measured by the addition of resazurin and an-
alyzed using the drug combination algorithm by Chou and
Talalay (35) (Figure 6A). Although some datapoints scored
as additive (primarily in PL21 cells), a majority of the data-
points in the other cell lines scored as synthetic lethal (CI <
0.8, red line). We next wanted to investigate if the 5-azadC
and Olaparib combination induced double stranded DNA
damage, similarly to what we observed in HeLa cells. The
HL60 cell line was treated with Olaparib and 5-azadC alone
or in combination and then scored for co-localization of
the double stranded DNA damage markers  -H2AX and
53Bp1. The combination treatment displayed a synergistic
induction of double stranded DNA damage (Figure 6B and
C, P < 0.05). We also stained the cells for the early apop-
totic marker phosphatidylserine using Annexin V in com-
bination with 7-AAD after 48 h exposure to the drug com-
bination. Quantiication of the double positive cell popula-
tion (7AAD/Annexin V) in the treatment groups showed a
signiicant increase in the 5-azadC and Olaparib group as
compared to the single drug treated cells (Figure 6D, P <
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Figure 4. 5-azadC cleaved fromDNA and 5-azadC inducedDNMT1 foci accumulate in XRCC1 defective cells. (A) EM9-V cells were treated with (6H-3H)
5-azadC and genomic DNA extracted. A known amount of genomic DNA was then incubated with whole cell lysates from EM9-V or EM9-XH cells for
the indicated time points. Insoluble DNA was precipitated and the resulting supernatant was analyzed for presence of 5-azadC in a liquid scintillation
counter. The standard and means of three independent experiments are shown. (B) In order to test if XRCC1 could be related with the repair of trapped
DNMT1, EM9-XH and EM9-V cells were transiently transfected with DNMT1-GFP plasmid and then treated with 15Mof 5-azadC for 24 h. After that,
they were allowed to recover for different times at which they were ixed and scored for DNMT1 foci. Cells with more than 10 foci were scored as positive.
The data represent the percentage of induced positive cells compared to control cells. The data from two independent experiments are shown. (C) XRCC1
deicient cells show a delay in the repair of chromatin bound DNMT1. Exponentially growing EM9-XH and EM9-V cells were treated for 24 h with 15
M of 5-azadC, washed and allowed to repair for different times at which they were lysed and processed for subcellular fractionation. (D) Validation
of the fractionation protocol showing the expected localization of GADPH, Ku70 and Histone H3 in the cytosolic- (cyt) nuclear soluble-, (nuc.sol.) and
chromatin- (chrom.) enriched fractions, respectively.
0.05), with an increase of cleaved PARP and phosphoryla-
tion of H2AX also evident (Figure 6E). The cells also dis-
played a progressive presentation of phosphatidylserine on
the outer membrane with a later uptake of the DNA dye
7AAD, proving that the cells die by apoptosis (Supplemen-
tary Figure S9).
DISCUSSION
There are different non-exclusive cytotoxic mechanisms of
action of 5-azadC; epigenetic changes in gene expression
causing cell death, trapping of DNMT onto DNA causing
lethal DNA damage and DNA damage generated by ran-
domly incorporated 5-azadC.Here, wewanted to determine
if BER could play a role in repair of 5-azadC-inducedDNA
lesions and also if it could promote survival. We utilized the
CHO BER (XRCC1) deicient cell system and demonstrate
the novel inding that XRCC1 deiciency sensitizes cell to 5-
azadC treatment. We also demonstrate that blocking BER
with the PARP inhibitor Olaparib cause synergistic lethal-
ity in HeLa cells and a panel of acute myeloid leukemia cell
lines.
A model for our proposed mechanism of action is pre-
sented in Figure 7. 5-azadC is incorporated in CpG is-
lands during normal replication as well as randomly in
the newly formed daughter strand instead of normal cy-
tosine. Our data demonstrate that both the excision of 5-
azadC from DNA and the generation of abasic sites oc-
cur independently of XRCC1 status. However, XRCC1
deicient cells display increased levels of SSBs and show
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Figure 5. Olaparib disrupts DNMT1/XRCC1 co-localization and traps SSBs intermediates of BER in cells treated with 5-azadC. (A) Quantiication of
cells positive for DNMT1 or XRCC1 foci after treatment with 5-azadC either alone or in combination with Olaparib. Cells with more than 10 foci were
scored as positive. The data are represented as fold increase in positive cells relative to control cells (value: 1). The means and SD of three independent
experiments are shown. (B) Co-localization of DNMT1 and XRCC1 foci in 5-azadC cells co treated with Olaparib as assessed by confocal microscopy.
HeLa cells were transiently transfected with plasmids encoding for DNMT1-GFP or XRCC1-RFP and treated with 5-azadC in combination with Olaparib
for 24 h. No sign of co-localization was observed in overlaid images. Experiments were repeated three times and representative images are shown. (C) HeLa
cells expressing the DNMT1-GFP plasmid were treated with 15Mof 5-azadC for 24 h. After that, they were able to recover in freshmedia with or without
the presence of 1 M of Olaparib for different times at which they were ixed and scored for DNMT foci. Cells with more than 10 foci were scored as
positive. The data represent the percentage of induced positive cells compared control cells. The data from two independent experiments are shown. (D)
SSB quantiication using ADU technique after a 24-h treatment with increasing concentrations of 5-azadC. EM9-XH and EM9-V cells were treated with
5-azadC alone or in combination with of the PARP inhibitor Olaparib (1 M) during the last 12 h. The means and SD of three independent experiments
are shown. (E and F) Quantiication of  -H2AX and RAD51 foci positive cells after a 24-h treatment with increasing concentrations of 5-azadC alone or
in combination with Olaparib (1M). Cells with more than 20 foci were scored as positive. The means and standard errors of two independent experiments
are shown. (G) Clonogenic survival of HeLa cells with increasing concentrations of 5-azadC for 24 h alone or in combination with Olaparib (0.3 M).
After that cells were washed and treated again with Olaparib until the ixation day. The means and standard deviation of two independent experiments are
shown. Statistical signiicance was determined using Student’s t-test, n.s. = non-signiicant, **P < 0.01, *P < 0.05.
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Figure 6. 5-azadC and Olaparib cause synergistic lethality in a panel of AML cell lines. (A)The AML cell lines HL60, K562, Mv4-11, KG1a and PL21
were incubated at optimal growth conditions in 96-well plates with either 5-azadC (50, 100, 200, 400 and 800 nM) or Olaparib (0.5, 1, 2, 4 and 8 M) or
in combination at all concentrations. After 72 h in the presence of the treatment, Resazurin was added and the absorbance measured. The Combination
Index (CI) was plotted against the Fraction affected (Fa) using the software CompusynTM, where CI < 0.8 is considered synergistic lethal (Red dotted
line). (B) Quantiication of  -H2AX and 53Bp1 foci positive cells after a 24 h treatment with 100nM of 5-azadC alone or in combination with Olaparib
(1 M). The means and SD of two independent experiments are shown. (C) Representative images of  -H2AX and 53Bp1 foci in HL60 cells. (D) The
AML cell line HL60 was incubated at optimal growth conditions with a combination of 250 nM 5-azadC and 2 M Olaparib for 48 h, single treatments
of 5-azadC and Olaparib or the combination of both was quantiied for both early (Annexin-V) and late apoptotic cells (Annexin-V + 7AAD). The data
show a signiicant increase in the induction of apoptotic cells in the combination group. The means and SD of three independent experiments are shown.
(E) Cells were also harvested for SDS-PAGE analysis. The combination treatment shows increased DNA damage ( -H2AX) and induction of apoptosis
(cleaved-PARP). *P < 0.05.
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Figure 7. Proposed model involving XRCC1 in the repair of 5-azadC induced lesions. 5-azadC is incorporated in CpG islands and randomly in the newly
formed daughter strand during replication. 5-azadC is excised from DNA independently of XRCC1 status, but in conditions of defective XRCC1 or
PARP inhibited cells, XRCC1 fails to localize to DNMT1 bound DNA, delaying repair. In XRCC1 deicient or PARP inhibited cells, delayed repair and
non-sealed ssDNA following 5-azadC excisions leads to replication fork collapse, DSBs and cell death.
a synergistic increase in SSBs when PARP inhibitors are
present. Taken together, these data demonstrate that BER
is actively removing 5-azadC from DNA. However, we be-
lieve that DNMT1–DNA adducts are most likely too big
to be removed by DNA glycosylases and are perhaps re-
moved by a base damage repairing enzyme like Tyrosyl
DNA Phosphodiesterase 1 (TDP1) (36) or TDP2 instead
(37). Our data also show that DNMT1 foci co-localize
with XRCC1. This could point to a previously unidenti-
ied role of XRCC1 in the clearance of bound DNMT1
from DNA. We tested this possibility by two different ap-
proaches and found thatXRCC1deicient cells have delayed
clearance of DNMT1–DNA adducts. This body of data, al-
though robust, is not enough to directly implicate XRCC1
in the repair of DNMT1–DNA adducts. Theoretically, af-
ter 5-azadC treatment, CpG islands could present clustered
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DNA damage comprised of DNMT adducts and SSBs gen-
erated form excision of naked 5-azadCTP. These SSBs could
potentially hinder the repair of trapped DNMT especially
when accumulated, as is the case in XRCC1 deicient cells.
Because PARP activity is required for eficient relocation
of XRCC1 to damaged sites (32), the XRCC1-DNMT1 co-
localization is abolished in the presence of PARP inhibitors,
causing delay in repair, increased DNA damage and syn-
thetic lethality in combination with 5-azadC.
Many patients receiving 5-azadC relapse or develop re-
sistance. Therefore, we reason that any combination that
increases the effect of this hypomethylating agent should
be carefully evaluated as a potentially improved therapeu-
tic opportunity. In recent years, PARP inhibitors have be-
come one of the most interesting options in the treatment
ofBRCA-mutant cancers (38,39). The mechanism of action
implicates a novel mechanism involving DNA repair. In
clinical trials, PARP inhibitors are used either as monother-
apy for the treatment of BRCA-mutated cancers or in com-
bination with other chemotherapeutics for the treatment of
solid cancers such as pancreatic, colorectal and cervical can-
cer (39). Here, we show that PARP inhibition using Ola-
parib perturbs BER in a XRCC1 dependent manner and
causes synergistic lethality with 5-azadC in acute myeloid
leukemia cell lines. Others have previously shown modest
effect of this combination treatment in some of the same
model systems using other PARP inhibitors (40). We be-
lieve that the additive effect demonstrated in that report is
largely due to dosing, as we also observe an additive effect at
lower doses of Olaparib. Nevertheless, our data clearly sug-
gest that perturbation of BERusingOlaparib could be a po-
tential approach to increase eficacy of 5-azadC treatment.
Current applied maximum tolerated doses of 5-azadC have
been established based on the wide range of side effect it ex-
erts on disease free proliferating tissue.We think that the full
therapeutic potential of 5-azadC and related agents have yet
to be discovered because of this. By targeting therapy to
stratiied patients carrying XRCC1 deiciency, or combin-
ing 5-azadC with a PARP inhibitor we could improve the
effects of the hypomethylating agent.
An increasing number of reports have shown a correla-
tion between single nucleotide polymorphism (SNP) of the
XRCC1 gene and the risk to develop various cancers, in-
cluding AML (41,42). There is evidence that some of the
XRCC1 polymorphisms found in cancer cells correlate with
defects in the repair of DNA damage induced by several
anti-cancer agents (43–45). Our data clearly indicate that
XRCC1 deiciency perturbs the BER pathway and sensi-
tizes cancer cells to 5-azadC treatment. It would be interest-
ing to investigate if XRCC1 polymorphisms correlate with
hypersensitivity to 5-azadC. If this is the case, AMLpatients
carrying defects in XRCC1 function could be stratiied for
5-azadC treatment, resulting in a more effective option.
Taken together, our results offer evidence for an impor-
tant therapeutic potential of BER deiciency and PARP in-
hibition when combined with 5-azadC. Our data warrant
further investigation in order to improve the already pos-
itive trends seen when treating myeloid malignancies with
5-azadC and 5-azaC.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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